Stephen Jaeger

Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ.

Houghton Mifflin Harcourt Publishing Co. is a learning company, which engages in instructional curriculum, assessment, technology, and professional learning. The company was founded in 1832 by William Ticknor and James Fields and is headquartered in Boston, MA.

Aradigm Corp. was a pharmaceutical company, which was focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists. The company was founded in 1991 and was headquartered in Hayward, CA.

Applera Corp. manufactures medical instruments

Part of Vivendi SE, Clinical Communications Group is a private company that provides outsourced marketing services. The company is based in Greenwich, CT. Clinical Communications Group was acquired by Snyder Communications, Inc., part of Vivendi SE from September 27, 2000 on August 27, 1998 for $108 million.

DARA BioSciences, Inc. is a pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products. The company's product portfolio includes Soltamox, Gelclair, Bionect and KRN5500. Soltamox offers a choice to patients who prefer or need a liquid form of tamoxifen. Gelclair is an alcohol-free bioadherent oral rinse gel for rapid and effective relief of pain associated with oral mucositis caused by chemotherapy and radiation treatment. The company markets Bionect, a topical treatment for skin irritation and burns associated with radiation therapy, in U.S. oncology/radiology markets. DARA BioSciences was founded by Steven Gorlin on June 22, 2002 and is headquartered in Raleigh, NC.